Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.79 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.56 |
| ▸ | TFEB | P19484 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457033 | 1.00 | NFE2L2 (0.79) | NFE2L2TRPM8KDM4ECYP1A1CYP1A2 | |
| SCHEMBL1056670 | 1.00 | NFE2L2 (0.79) | NFE2L2TRPM8KDM4ECYP1A1CYP1A2 | |
| 2,6-Dimethoxybenzoic Acid SCHEMBL8133347 | 0.93 | NFE2L2 (0.68) | NFE2L2TRPM8KDM4ECYP1A1CYP1A2 | |
| 2,6-Dimethoxybenzoic Acid SCHEMBL8133343 | 0.93 | NFE2L2 (0.68) | NFE2L2TRPM8KDM4ECYP1A1CYP1A2 | |
| SCHEMBL2744353 | 0.88 | NFE2L2 (1.00) | NFE2L2TRPM8KDM4ECYP1A1CYP1A2 | |
| SCHEMBL2744350 | 0.88 | NFE2L2 (1.00) | NFE2L2TRPM8KDM4ECYP1A1CYP1A2 | |
| SCHEMBL6844087 | 0.87 | NFE2L2 (0.74) | NFE2L2TRPM8CYP1A1CYP1A2CYP2D6 | |
| SCHEMBL6844089 | 0.87 | NFE2L2 (0.74) | NFE2L2TRPM8CYP1A1CYP1A2CYP2D6 | |
| SCHEMBL14950768 | 0.87 | NFE2L2 (0.79) | NFE2L2TRPM8KDM4ECYP1A1CYP1A2 | |
| SCHEMBL14691500 | 0.86 | NFE2L2 (0.60) | NFE2L2TRPM8KDM4ECYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747032-B2 | DOUBLE ALPHA 2/5-HT 2C ANTAGONISTS USED TO TREAT DEPRESSION, IMPULSIVE BEHAVIOUR DISORDERS, ANXIETY, SCHIZOPHRENIA, PARKINSON'S DISEASE, COGNITIVE DISORDERS AND DISORDERS INVOLVING SEXUAL FUNCTION, SLEEP AND EATING | LES LABORATOIRES SERVIER (FR) | 2004-06-08 | — | — | US | disclosed |
| EP-0863136-B1 | Derivatives of azetidine and pyrrolidine | AKZO NOBEL NV (NL) | 2003-09-24 | — | — | EP | disclosed |
| US-20030087916-A1 | Pyrimidin-4-one compounds | LES LABORATOIRES SERVIER (FR) | 2003-05-08 | — | — | US | disclosed |
| US-6403573-B1 | BICYCLIC-CARBO OR HETERO OXY OR BICYCLIC CARBO OR HETERO SULFIDE CONTAINING PYRROLIDINE/AZETIDINE DERIVATIVES USED AS ANTIDEPRESSANT OR PREVENTING SEROTONIN-RELATED DISEASES | AKZO NOBEL N.V. (NL) | 2002-06-11 | — | — | US | disclosed |
| US-20020040016-A1 | Derivatives of azetidine and pyrrolidine | MERCK SHARP & DOHME B.V. (NL) | 2002-04-04 | — | — | US | disclosed |
| US-6281243-B1 | ANTIDEPRESSANTS, ANTISEROTONINE AGENT | AKZO NOBEL N.V. (NL) | 2001-08-28 | — | — | US | disclosed |
| WO-1999043647-A1 | DERIVATIVES OF AZETIDINE AND PYRROLIDINE | AKZO NOBEL N.V. (NL) | 1999-09-02 | — | — | WO | disclosed |
| EP-0863136-A1 | Derivatives of azetidine and pyrrolidine | Akzo Nobel N.V. (NL) | 1998-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040016-A1 | Derivatives of azetidine and pyrrolidine | TPH1, TPH2, HTR1D | NFE2L2 803/4885TRPM8 3782/4885KDM4E 1344/4885 |
| US-20030087916-A1 | Pyrimidin-4-one compounds | HTR2C, HTR1A, HTR4 | NFE2L2 629/4885TRPM8 1140/4885KDM4E 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.